Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin for Elective Surger or Procedure - the BRIDGE Trial: Design, Rationale and Clinical Implications
Bibliographic record
Abstract
Abstract Abstract 4327 Background: Low-molecular-weight heparin (LMWH) bridging, usually in treatment doses, may be used in patients with atrial fibrillation (AF) on chronic warfarin who require interruption for an invasive procedure or surgery to minimize the period of sub-therapeutic anticoagulation with the aim of reducing perioperative thromboembolism, as warfarin interruption and surgery may confer a prothrombotic state. However, the efficacy and safety of LMWH bridging therapy has not been tested in a rigorous and large randomized trial. We describe the design of the BRIDGE Trial, explain the rationale for the study population and bridging dose regimen, and discuss its implications for clinical practice. Hypothesis: No bridging is non-inferior to LMWH bridging for the prevention of arterial thromboembolism and is superior to bridging for perioperative bleeding. Design: BRIDGE is a NHLBI-funded randomized, multi-center, placebo-controlled trial assessing a standardized bridging protocol (NCT00786474). Population: 3,626 adults with AF from at least 45 centers in the United States and Canada with ≥1 additional stroke risk factor who require interruption of warfarin for surgery/invasive procedure and do not have a prior stroke (within 12 weeks), major bleeding (within 6 weeks), severe renal insufficiency (CrCl <30 mL/min), thrombocytopenia (<100,000 × 109/L) or contraindication to perioperative LMWH. Intervention: Dalteparin, 100 IU/kg SC twice-daily, before and after surgery compared to SC placebo injections. Outcomes: 1) primary outcomes: arterial thromboembolism (ischemic stroke, transient ischemic attack or systemic embolism) and major bleeding from perioperative Day −5 to Day +30; 2) secondary outcomes: acute coronary syndrome, venous thrombosis, minor bleeding. Analysis: Comparison of prespecified outcomes in LMWH and placebo groups. Summary: BRIDGE is an ongoing trial designed to definitively assess the efficacy and safety of LMWH bridging in patients with AF who require interruption of warfarin for an invasive procedure or surgery and aims to establish a standard-of-care for patients who require perioperative interruption of anticoagulants. Disclosures: Spyropoulos: sanofi: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Eisai: Consultancy; Pfizer: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau. Off Label Use: Low molecular weight heparin dalteparin for bridging therapy. Douketis:sanofi: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau, event adjudication; bristol meyer squibb: event adjudication; Pfizer: Speakers Bureau; boehringer-ingelheim: Membership on an entity’s Board of Directors or advisory committees. Kaatz:Boehringer-Ingelheim: Consultancy, Research Funding, Speakers Bureau; Bristol Myer Squibb: Consultancy, Research Funding; Bayer: Research Funding; National Institute of Health: Research Funding; Canadian Institute of Health Research: Research Funding; Pfizer: Consultancy; Johnson and Johnson: Consultancy; Ortho-McNeil: Consultancy; GlaxoSmithKline: Speakers Bureau; AC Forum: Membership on an entity’s Board of Directors or advisory committees; National Certification Board of Anticoagulation Providers: Membership on an entity’s Board of Directors or advisory committees; National Blood Clot Alliance: Membership on an entity’s Board of Directors or advisory committees. Ortel:Eisai: Research Funding; Instrumentation Laboratory: Consultancy; GSK: Research Funding.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.006 | 0.006 |
| Meta-epidemiology (narrow) | 0.002 | 0.001 |
| Meta-epidemiology (broad) | 0.003 | 0.002 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.003 | 0.002 |
| Insufficient payload (model declined to judge) | 0.006 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".